Enterprise Innovation | Weill Cornell Medicine

Based in New York City, Weill Cornell Medicine Enterprise Innovation engages and collaborates with Weill Cornell Medicine faculty and trainees while fostering alliances with leaders in the biomedical industry and business and investment community. Our focus is to translate the application of emerging science and new technologies into world-class medical breakthroughs.

Integrating Weill Cornell Medicine’s different teams and resources under a single, united organization, Enterprise Innovation encompasses the entire spectrum of an effective innovation ecosystem. We offer unique opportunities for faculty and trainees to transform their research into medical advances through collaborations including access to the Sanders Tri-Institutional Therapeutics Discovery Institute.

Enterprise Innovation Metrics from FY18 to FY23

520

New Tech Disclosures

183

Issued US Patents

152

Licenses and Options

NewCo Launches

For Inventors and Innovators

Learn about how to collaborate with our team of top-tier business development professionals to bring your innovations to life.

Two men in dark blue suits shaking hands and two women at the table smiling

For Industry, Investors and Partners

Learn about groundbreaking innovations you can partner to fuel a pipeline or launch a new venture.

A Caucasian and an Indian woman holding some booklets and talking

Innovation Ecosystem

Learn more about the infrastructure and different components of Enterprise Innovation.

Four medical students in white coats sitting at a table and listening to a lecture

Programs, Offerings and Support

Explore entrepreneurial programming and education offered by Enterprise Innovation and our ecosystem partners.

Technology Portfolio

Enterprise Innovation brings together the power of industry-leading translational research and clinical care combined with top-tier business development expertise to accelerate innovation to market. Our leading technology portfolio encompasses major pillars of biomedical innovation.

We also provide access to a diverse selection of tangible materials developed by Weill Cornell Medicine investigators. See the most updated catalog of our ready-for-licensing tangible materials here.

Two doctors and two business reps talking

Collaboration Opportunities

Check out our available research opportunities for potential collaborations.

Events

A Caucasian women with long brunette hair typing on a laptop in an engineering lab

Nov 20,2024

9:00am to 5:00pm

NSF I-Corps Regional Course (Application Deadline: 11/20/24)

Nov 20,2024

12:00pm to 1:00pm

Lab to Impact: Commercialization and Venture Module on Founder's

Nov 22,2024

9:00am to 11:30pm

Manufacturing Hardware Accelerator at Rev: Ithaca Startup Works

Event details with a photo of seminar lecturer NatalieDeana Badillo, a young Asian woman with long black hair and wearing a white coat

Nov 22,2024

12:00pm to 2:00pm

3D Printing Seminar

Testimonials

John P. Leonard, M.D., Senior Associate Dean of Innovation and Initiatives

Getting new innovations across the finish line requires collaboration, often with industry partners, to scale up findings for application in healthcare. Ultimately, we want the work we do here to have a real impact on patients. By fostering an entrepreneurial environment, we can do that.

Lisa Placanica, Ph.D., Senior Managing Director of the Center for Technology Licensing

There’s obviously fantastic research being done at Weill Cornell Medicine. So we want to work with faculty to identify aspects of their research that could be shaped into a product or a service, work with them to develop it and then to forge the partnership with a commercial entity. We also have to have a finger on the pulse of what industry is looking for: what venture firms are investing in, what pharma is trying to fill their pipeline with. And then we make connections between the two. We have to speak the language between the commercial enterprise and the academic researcher.

Randi B. Silver, Ph.D., Associate Dean and Professor of Physiology and Biophysics

Enterprise Innovation has galvanized us to move forward as basic scientists, and to look for translational aspects that could be developed, with an industrial partner, for patient care. As a result, we have been able to get traction in exploring various avenues for commercialization with angel investors, pharma, venture capital and, significantly, our own Tri-Institutional Therapeutics Discovery Institute, none of which would have been possible without support from the Daedalus Fund for Innovation.

Ronald G. Crystal, M.D., Chair of Genetic Medicine and Professor of Medicine

Allying with the right industrial partner is a vital factor in attracting investors, and Enterprise Innovation’s relationships with and access to biopharma and life science leaders make it possible for aspiring scientist/entrepreneurs to find the right match.

News

Three researchers (two women and a men on the right) wearing white coats in a lab

In-House Gene Therapy Core Facility Helps Move Novel Products from the Bench to the Clinic

November 19, 2024

With the 25th anniversary of the Belfer Gene Therapy Core Facility approaching next year, Dr. Stephen Kaminsky, professor of research in genetic medicine and associate director of the facility, shared with us the history and successes of this cutting-edge research facility. It has played a vital role in supporting Cornell University, the National Institutes of Health (NIH) and other U.S. and international investigators in constructing, producing and testing clinical gene therapy vectors.

New Genetic Signatures Can Classify Breast Cancers and Guide Prognosis

October 4, 2024

Researchers at Weill Cornell Medicine have developed breast cancer cell-of-origin signatures that can better predict both overall and progression-free survival of patients with breast cancer compared to previously developed genomic signatures.

Translating Research into Next Generation Care Through Collaboration